Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study NB32 (32 mg naltrexone SR + 360 mg bupropion SR) significantly reduced depressive symptoms and promoted weight loss in overweight and obese women with MDD over 24 weeks, with 95% showing clinical improvement and 70% achieving remission, while maintaining a safety profile consistent with its components
PMCID: PMC11091273 Morsali S, Sabahi Z, Kakaei J, Hakimzadeh Z, Hamidi S, Gholipour-Khalili E, Sanaie S, Talebi M, Naseri A (2023) Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review
Pain 115 (1-2), 6070
How you can reduce the risk of suffering from B12 deficiency By reducing alcohol consumption or stopping drinking alcohol, the risk of B12 deficiency can be reduced
This one-size-fits-all approach may contribute to inconsistent clinical results and underlines the need for personalized treatment strategies [57]